EIPICO

Name

EIPICO

Legal name

Egyptian International Pharmaceutical Industries Company

Website

https://eipico.com.eg

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851)

akta.pro primary industry

Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)

akta.pro secondary industries

Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Rigid Pharmaceutical & Healthcare Plastic Packaging (Pill Bottles, Vials, Med-Grade Jars) (IMALAAAE), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Biosimilar production
• Sterile injectables
• Contract manufacturing

Headquarters

HQ city

Tenth Of Ramadan City

HQ country

Egypt

HQ region

Africa

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. Pharmaceutical Products Sales - Domestic: Sale of over 400 pharmaceutical products covering 25 therapeutic classes to the Egyptian market through pharmacies and hospitals. Products include antibiotics, antivirals, ophthalmics, cardiovascular drugs, and more.
2. Pharmaceutical Products Export: Export of pharmaceutical products to 67 countries worldwide. EIPICO holds license agreements with international pharmaceutical companies to produce their products locally. Also exports semi-finished contract manufacturing products.
3. Contract Manufacturing: Semi-finished and finished product manufacturing under license agreements with multinational pharmaceutical companies. Manufacturing for Batterjee Pharma in Saudi Arabia (30% owned joint venture).
4. Primary Packaging Materials: EIACO affiliate manufactures and sells primary packaging materials including ampoules, vials, and aluminum tubes to other pharmaceutical companies in Egypt.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

EIPICO manufactures and markets over 400 pharmaceutical products across 25 therapeutic classes (antibiotics, antivirals, ophthalmics, cardiovascular, respiratory, gastrointestinal, dermatological, analgesics, corticosteroids, biosimilars) from facilities in Tenth of Ramadan City, Egypt. The company also performs contract manufacturing under license for international pharmaceutical companies, produces primary packaging materials (ampoules, vials, dropper bottles) through its EIACO and Plastic Factory affiliates, and exports to 67+ countries.

Product overview

EIPICO (Egyptian International Pharmaceutical Industries) is a leading Egyptian pharmaceutical company manufacturing over 400 pharmaceutical products across 25+ therapeutic classes. The product portfolio spans antibiotics (including cephalosporins, penicillins, fluoroquinolones), analgesics/antipyretics (paracetamol products), cardiovascular medications, respiratory treatments, ophthalmic products, dermatological products, gastrointestinal medications, antihistamines, corticosteroids, and biologicals/biosimilars. Key product lines include: Cetal (paracetamol) line with tablets, caplets, oral suspension, drops, and suppositories; E-MOX (amoxicillin) antibiotics; BRONCHOLIN respiratory products; DEXATOBRIN ophthalmic solutions; and the newly launched ADALIMAB biosimilar from EIPICO 3 facility. The company operates manufacturing facilities including Factory 1 (established 1980), Factory 2 (2013), EIPICO 3 (biologicals/biosimilars), Plastic Factory, and affiliate EIACO for primary packaging materials.

Differentiator

Problem solved

Functional benefit

Brands

• Episovir: Anti-viral product used in Egypt 2030 with No Virus-C initiative, provided free to Egyptian public hospitals
• EIPICO 3
• EPIC
• E-CPD

Quantifiable outcome

• 26% of Egypt's total pharmaceutical exports
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and key.

• Unified Procurement Agency (Egypt)coreChannel Partner/ Reseller/ Distributor · 11 December 2025ADALIMAB biosimilar awarded to be supplied to Unified Procurement Agency to ensure availability to large segment of patients.
• Al Dana Medical Company (Qatar)keyChannel Partner/ Reseller/ Distributor · 9 September 2025Strategic partnership agreement signed in Doha for marketing and distribution of EIPICO's pharmaceutical products in Qatar. Al Dana Medical Company has extensive experience and strong relationships in Qatar's healthcare sector.
• Propharma Distribution Company (Uzbekistan)keyChannel Partner/ Reseller/ Distributor · 14 July 2025Agreement signed for Propharma to distribute EIPICO's products in Uzbekistan. Part of efforts to increase exports and enhance presence in Uzbekistan and neighboring countries.
• LAFZ Pharmaceuticals (Uzbekistan)keyChannel Partner/ Reseller/ Distributor · 14 July 2025MOU signed allowing ACDIMA's companies to manufacture their products at LAFZ's factory in Tashkent, Uzbekistan.
• Reliance Life Sciences (India)coreTechnology or Integration · 13 March 2025Indian biotechnology company providing technology and expertise for biosimilar manufacturing. EIPICO 3 factory utilizes process standards set by Reliance Life Science for manufacturing monoclonal antibodies and recombinant protein products.
• Supreme Council of University HospitalskeyStrategic or Co-development Partner · 9 March 2025Cooperation agreement signed to support national institutional identity of university hospitals, enhance programs for developing capabilities of healthcare providers including doctors, pharmacists, and nurses in university hospitals.
• ARAB API (Arab Company for Active Pharmaceutical Ingredients)coreStrategic or Co-development Partner · 30 December 2024Joint venture for establishing first multi-purpose factory in Egypt and Middle East for pharmaceutical raw materials. Contributions: ACDIMA 60%, EIPICO 30%, SCZONE Investment Company 10%. Land of 96,828 sqm in Ain Sokhna. Investments of USD 165 million.
• German International University (GIU)coreStrategic or Co-development Partner · 22 October 2024MOU signed for academic and industry collaboration to promote education needs, job market requirements, and real opportunity for students to practice sciences. Training programs set for students of Faculties of Pharmaceutical Engineering and Biotechnology lasting five consecutive months.
• Kazakhstan Government (Ministry of Health, Kazakhstan Invest, QIC)keyStrategic or Co-development Partner · 16 September 2024Discussions for implementing Egy Kazakh Pharmaceutical Park in Kazakhstan with investments up to 33 million USD, providing 200 job opportunities. Kazakh city of Almaty chosen for factory establishment to localize pharmaceutical industry in Kazakhstan.
• Pharmadule Morimatsu AB (Sweden)coreTechnology or IntegrationSwedish company that designed and fabricated prefabricated modular structure building techniques for EIPICO 3 biological and biosimilar facility. Modules were designed and equipped abroad, shipped to Egypt, and installed. EIPICO applied this construction concept to ensure highest standards and guarantee performance efficacy.
• Batterjee Pharma (Saudi Arabia)coreStrategic or Co-development PartnerEIPICO owns 30% stake in Batterjee Pharma joint venture established in Saudi Arabia. First EIPICO investment abroad in manufacturing pharmaceutical products. Started production in 2009 in Jeddah Industrial Zone Phase IV, manufacturing 30 products exported to Bahrain, UAE, and Yemen.

Scale indicators21 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Cipla: Indian-headquartered global generic manufacturer with strong MENA and African presence. Comparable in generic antibiotics, antiretrovirals, and biosimilars, and competes with EIPICO in African and CIS export markets.
• Aurobindo Pharma: Large Indian generic manufacturer with significant MENA, African, and European export business. Comparable in injectable and oral generic product portfolio competing for the same regional tenders as EIPICO.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generics and injectables manufacturer with extensive MENA presence. Comparable to EIPICO in therapeutic categories (antibiotics, injectables) and geographic reach, though at substantially larger scale.

Direct peers

• Eva Pharma: Major Egyptian pharmaceutical manufacturer with broad generic portfolio and growing biosimilars and exports business. Directly comparable to EIPICO as a fellow top-tier Egyptian pharma with antibiotic, ophthalmic, and biosimilar exposure targeting MENA/Africa.
• Julphar (Gulf Pharmaceutical Industries): UAE-based generics and biosimilars manufacturer serving MENA. Competes with EIPICO in regional tenders and biosimilar pipelines, with similar regulatory certification profile (EU GMP, WHO PQ).
• Tabuk Pharmaceuticals: Saudi pharmaceutical manufacturer with branded generics, biologics, and biosimilars. Comparable to EIPICO in product mix, regional export ambitions, and biosimilar strategy targeting MENA markets.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi-listed pharmaceutical manufacturer producing generics and licensed products for the Saudi/GCC market. Directly comparable as a regional pharma peer with similar product breadth, regulatory certifications, and MENA distribution model.
• Pharco Pharmaceuticals: Largest Egyptian pharmaceutical manufacturer by some measures, focused on generics, antibiotics, and hepatitis treatments. Competes head-to-head with EIPICO in the Egyptian market and across export markets, including biosimilars.
• Medical Union Pharmaceuticals (MUP): Egyptian pharmaceutical company in which EIPICO holds a 10% stake (acquired 2020). Direct peer as a fellow Egyptian pharma manufacturer; EIPICO's investment also signals strategic overlap and partnership potential.

Regional players

• Marcyrl Pharmaceutical Industries: Egyptian pharmaceutical manufacturer focused on generics, injectables, and biosimilars. Comparable in product categories and Egyptian-market positioning, with growing biosimilar pipeline similar to EIPICO 3.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/eipico_official?lang=en
• YouTubeyoutube.com/channel/UCmTcRD83a8OuTBBHzU4rA-w
• Facebookfacebook.com/EIPICO.Official
• LinkedInlinkedin.com/company/eipico-official
• Instagraminstagram.com/eipico.official?igshid=1r8b6bxng9d67

Compliance22 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EIPICO